

Details of the Contributions of Individual Authors

Toshiyuki Fukao and Naomi Kondo performed the enzyme assays, immunoblot/mutation analysis, and expression analysis of cDNAs. Toshiyuki Fukao mainly wrote this manuscript. Shinsuke Maruyama, Toshihiro Ohura, Mitsuo Toyoshima, Naomi Kuwada, and Mari Imamura are the physicians responsible for the patients. Yuki Hasegawa and Seiji Yamaguchi performed gas chromatography-mass spectrometry and tandem mass spectrometry analyses and first suspected the disorder. Isao Yuasa confirmed GK77 and 77b as identical twins by DNA analyses. Antti M Haapalainen and Rik K Wierenga analyzed the tertiary structural effects of the mutations.

References to Electronic Databases

Alpha-methylacetoacetic aciduria, mitochondrial acetoacetyl-CoA thiolase deficiency (OMIM 203750, 607809)

Mitochondrial acetoacetyl-CoA thiolase, acetyl-CoA acetyltransferase 1 (EC 2.3.1.9)

ACAT1 gene (gene ID 38, NM_000019.3)

Details of Funding

This study was in part supported by Health and Labor Science Research Grants for Research on Intractable Diseases and Research on Children and Families from the Ministry of Health, Labor and Welfare of Japan and by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science, Sports and Culture of Japan

Details of Ethics Approval

This study has been approved by the Ethical Committee of the Graduate School of Medicine, Gifu University.

References

- Daum RS, Lamm PH, Mamer OA, Scriver CR (1971) A "new" disorder of isoleucine catabolism. *Lancet* 2:1289–1290
- Fukao T, Yamaguchi S, Kano M et al (1990) Molecular cloning and sequence of the complementary DNA encoding human mitochondrial acetoacetyl-coenzyme A thiolase and study of the variant enzymes in cultured fibroblasts from patients with 3-ketothiolase deficiency. *J Clin Invest* 86:2086–2092
- Fukao T, Yamaguchi S, Orii T, Hashimoto T (1995) Molecular basis of beta-ketothiolase deficiency: mutations and polymorphisms in the human mitochondrial acetoacetyl-coenzyme A thiolase gene. *Hum Mutat* 5:113–120
- Fukao T, Song XQ, Mitchell GA et al (1997) Enzymes of ketone body utilization in human tissues: protein and messenger RNA levels of succinyl-coenzyme A (CoA):3-ketoacid CoA transferase and mitochondrial and cytosolic acetoacetyl-CoA thiolases. *Pediatr Res* 42:498–502
- Fukao T, Nakamura H, Song XQ et al (1998) Characterization of N93S, I312T, and A333P missense mutations in two Japanese families with mitochondrial acetoacetyl-CoA thiolase deficiency. *Hum Mutat* 12:245–254
- Fukao T, Scriver CR, Kondo N (2001) The clinical phenotype and outcome of mitochondrial acetoacetyl-CoA thiolase deficiency (beta-ketothiolase or T2 deficiency) in 26 enzymatically proved and mutation-defined patients. *Mol Genet Metab* 72:109–114
- Fukao T, Nakamura H, Nakamura K et al (2002) Characterization of six mutations in five Spanish patients with mitochondrial acetoacetyl-CoA thiolase deficiency: effects of amino acid substitutions on tertiary structure. *Mol Genet Metab* 75:235–243
- Fukao T, Zhang GX, Sakura N et al (2003) The mitochondrial acetoacetyl-CoA thiolase (T2) deficiency in Japanese patients: urinary organic acid and blood acylcarnitine profiles under stable conditions have subtle abnormalities in T2-deficient patients with some residual T2 activity. *J Inher Metab Dis* 26:423–431
- Fukao T, Shintaku H, Kusubae R et al (2004) Patients homozygous for the T435N mutation of succinyl-CoA:3-ketoacid CoA Transferase (SCOT) do not show permanent ketosis. *Pediatr Res* 56:858–863
- Fukao T, Zhang G, Rolland MO et al (2007) Identification of an Alu-mediated tandem duplication of exons 8 and 9 in a patient with mitochondrial acetoacetyl-CoA thiolase (T2) deficiency. *Mol Genet Metab* 92:375–378
- Fukao T, Boneh A, Aoki Y, Kondo N (2008) A novel single-base substitution (c.1124A > G) that activates a 5-base upstream cryptic splice donor site within exon 11 in the human mitochondrial acetoacetyl-CoA thiolase gene. *Mol Genet Metab* 94:417–421
- Fukao T, Horikawa R, Naiki Y et al (2010a) A novel mutation (c.951 C > T) in an exonic splicing enhancer results in exon 10 skipping in the human mitochondrial acetoacetyl-CoA thiolase gene. *Mol Genet Metab* 100:339–344
- Fukao T, Nguyen HT, Nguyen NT et al (2010b) A common mutation, R208X, identified in Vietnamese patients with mitochondrial acetoacetyl-CoA thiolase (T2) deficiency. *Mol Genet Metab* 100:37–41
- Haapalainen AM, Merilainen G, Pirila PL, Kondo N, Fukao T, Wierenga RK (2007) Crystallographic and kinetic studies of human mitochondrial acetoacetyl-CoA thiolase: the importance of potassium and chloride ions for its structure and function. *Biochemistry* 46:4305–4321
- Kano M, Fukao T, Yamaguchi S, Orii T, Osumi T, Hashimoto T (1991) Structure and expression of the human mitochondrial acetoacetyl-CoA thiolase-encoding gene. *Gene* 109:285–290
- Kimura M, Yamamoto T, Yamaguchi S (1999) Automated metabolic profiling and interpretation of GC/MS data for organic acidemia screening: a personal computer-based system. *Tohoku J Exp Med* 188:317–334
- Kobayashi H, Hasegawa Y, Endo M, Purevsuren J, Yamaguchi S (2007) A retrospective ESI-MS/MS analysis of newborn blood spots from 18 symptomatic patients with organic acid and fatty acid oxidation disorders diagnosed either in infancy or in childhood. *J Inher Metab Dis* 30:606
- Lehnert W (1994) Long-term results of selective screening for inborn errors of metabolism. *Eur J Pediatr* 153:S9–S13
- Nakamura K, Fukao T, Perez-Cerda C et al (2001) A novel single-base substitution (380 C > T) that activates a 5-base downstream cryptic splice-acceptor site within exon 5 in almost all transcripts in the human mitochondrial acetoacetyl-CoA thiolase gene. *Mol Genet Metab* 72:115–121

- Niwa H, Yamamura K, Miyazaki J (1991) Efficient selection for high-expression transfectants with a novel eukaryotic vector. *Gene* 108:193–199
- Robinson BH, Sherwood WG, Taylor J, Balfe JW, Mamer OA (1979) Acetoacetyl CoA thiolase deficiency: a cause of severe ketoacidosis in infancy simulating salicylism. *J Pediatr* 95:228–233
- Sakurai S, Fukao T, Haapalainen AM et al (2007) Kinetic and expression analyses of seven novel mutations in mitochondrial acetoacetyl-CoA thiolase (T2): identification of a Km mutant and an analysis of the mutational sites in the structure. *Mol Genet Metab* 90:370–378
- Wakazono A, Fukao T, Yamaguchi S et al (1995) Molecular, biochemical, and clinical characterization of mitochondrial acetoacetyl-coenzyme A thiolase deficiency in two further patients. *Hum Mutat* 5:34–42
- Zhang GX, Fukao T, Rolland MO et al (2004) Mitochondrial acetoacetyl-CoA thiolase (T2) deficiency: T2-deficient patients with “mild” mutation(s) were previously misinterpreted as normal by the coupled assay with tiglyl-CoA. *Pediatr Res* 56:60–64
- Zhang G, Fukao T, Sakurai S, Yamada K, Michael Gibson K, Kondo N (2006) Identification of Alu-mediated, large deletion-spanning exons 2–4 in a patient with mitochondrial acetoacetyl-CoA thiolase deficiency. *Mol Genet Metab* 89:222–226

原 著

カルニチンパルミトイルトランスフェラーゼ2欠損症のろ紙血 血清のアシルカルニチンプロファイルの経時的变化

岐阜大学大学院医学系研究科小児病態学¹⁾, 同 連合創薬医療情報研究科医療情報学専攻²⁾, 島根大学医学部小児科³⁾

久保田一生¹⁾ 深尾 敏幸¹⁾²⁾ 堀 友博¹⁾ 小林 弘典³⁾
船戸 道徳¹⁾ 長谷川有紀³⁾ 山口 清次³⁾ 近藤 直実¹⁾

要 旨

我々は、カルニチンパルミトイルトランスフェラーゼ(CPT)2欠損症の血液ろ紙、血清のアシルカルニチンプロファイルの出生後からの経時的变化を検討した。症例は日齢0の男児。切迫早産のため在胎37週0日、帝王切開にて出生した。姉がCPT2欠損症のため本症例もブドウ糖輸液を行い注意深い観察を行った。血液ろ紙、血清のアシルカルニチンプロファイルを経時的に分析し、以下の所見と姉がCPT2欠損症と酵素診断されていることから本症例は無症状であったがCPT2欠損症と化学診断した。血液ろ紙におけるC16-アシルカルニチン(C16)、C18:1アシルカルニチン(C18:1)、C18-アシルカルニチン(C18)は日齢3にピークとなり、カットオフ値を超えていたがその後カットオフ値以下となった。(C16+C18:1)/C2は生後14日までカットオフ値を超えており、スクリーニング指標として有用と考えられた。血清でもC16、C18:1、C18は日齢3にピークとなり、その後徐々に低下したが、日齢14まで常にカットオフ値を超えており、ろ紙血よりも血清におけるアシルカルニチン分析の方が確実に異常を指摘できた。ろ紙血による現行の採血時期における脂肪酸代謝異常症のスクリーニングでは、我々の症例のようにすでにC16、C18、C18:1がカットオフ値を下回り偽陰性となる可能性がある。このようなCPT2欠損症例を見逃さないためにはスクリーニング時期をより早期に設定する必要性が示唆された。

キーワード: CPT2欠損症, 脂肪酸β酸化障害, アシルカルニチン,
タンデムマススペクトロメトリー, 新生児マススクリーニング

はじめに

カルニチンパルミトイルトランスフェラーゼ(CPT)2欠損症は、常染色体劣性遺伝形式を示し、ミトコンドリア脂肪酸β酸化障害をきたす疾患の1つである。ミトコンドリアにおける脂肪酸β酸化系は肝臓ではブドウ糖からのエネルギー供給が低下したときなどに作動してアセチル-CoAやケトン体など代替エネルギーを産生する。また脂肪酸β酸化系は心臓や骨格筋においては安静時のエネルギー産生において重要である。長鎖脂肪酸が細胞質からミトコンドリア内に輸送される際にカルニチンシャトルが必要である。長鎖脂肪酸が活性化されたアシル-CoAはミトコンドリア外膜に存在するCPT1により、アシルカルニチンとなる。アシルカルニチンはカルニチンアシルカルニチ

ントランスロカーゼによりミトコンドリア内膜を通過し、CPT2により再びアシル-CoAへ変換される。CPT2に異常があるとミトコンドリア内でアシルカルニチンからアシル-CoAへの変換が障害され、β酸化を受けることができず、アシルカルニチンが蓄積する。このように脂肪酸代謝が十分に行われず、エネルギー産生が低下することで発症する。

CPT2欠損症は本邦におけるタンデム型質量分析計(以下タンデムマス)によるマススクリーニング・パイロット研究などの報告によれば、比較的頻度の高い脂肪酸酸化異常症である¹⁾。

臨床型は大きく出生前発症型、乳幼児発症型、軽症型(骨格筋型)の3つに分類される。出生前発症型は腎異形性、大脳奇形、顔貌異常など認め、致死性である。乳児発症型は低ケトン性低血糖の発作として発症し、乳幼児突然死やReye様症候群と関連がある。軽症型(骨格筋型)は成人期に偶発性横紋筋融解症で発症する²⁾。

我々は以前1歳3か月にReye様症候群で発症したCPT2欠損症症例を経験した³⁾。今回その次子で、出生

(平成22年3月23日受付)(平成23年1月17日受理)

別刷請求先: (〒501-1194) 岐阜市柳戸1-1

岐阜大学大学院医学系研究科小児病態学

久保田一生

E-mail: kubotak@gifu-u.ac.jp




図1 生後12時間後のろ紙血アシルカルニチンプロファイル
 横軸はm/z値、縦軸は相対量を示した。図右に各アシルカルニチンの定量値(μmol/l)と括弧内に上限または下限カットオフ値を示した。*は内部標準物質。C0, C2に比較してC16, C18:1, C18などの長鎖アシルカルニチンが高く、(C18:1+C16)/C2も上昇しており、CPT2欠損症に特徴的なパターンである。

直後から経過観察し、生後12時間後から経時的に血清、ろ紙血のアシルカルニチン推移を観察し、CPT2欠損症と化学診断できた症例を経験した。タンデムマスによる新生児スクリーニングの実施時期を考える上で貴重な経験であると考え報告する。

症 例

在胎週数37週0日、出生体重2,600g、男児。

家族歴：姉がCPT2欠損症で当科にて加療中。姉は1歳3か月にReye様症候群にて発症した。発作時の有機酸分析にて低ケトン性ジカルボン酸尿、アシルカルニチン分析にてCPT2欠損症が疑われた。線維芽細胞を用いたCPT2活性がコントロールの16%と低下しておりCPT2欠損症と診断した。ゲノムレベルでの遺伝子解析では父由来のCPT2遺伝子にE174K変異が同定されたが、母由来の変異は同定されなかった³⁾。

母親の妊娠経過：次子妊娠にあたり、遺伝相談を実施した。姉で母由来の変異は同定されておらず、出生前に遺伝子解析を行っても保因者か患者かの区別がつけられないこと、新生児期に十分なグルコースの補給で新生児期発症を予防できる可能性が高いことを説明し、両親の希望で出生前検査は行わずに妊娠は継続された。妊娠36週6日、切迫早産にて入院。翌日緊急帝王切開となった。

出生後の経過：アプガースコア1分9点、5分10点で仮死なく出生。体温36.8℃、呼吸数54回/分、心拍数134回/分、血圧59/30mmHgで活気は良好であった。大泉門は平坦、肺野は清、心音は整、腹部は平坦

で軟、筋トーン低下や外表奇形を認めなかった。血液生化学検査では、アンモニア値は出生後157μg/dlとやや高値であったが、生後3日には100μg/dl以下となり一過性であった。血糖値は46mg/dlと著明な低血糖(40mg/dl以下)は認めず、その後も低血糖は認めなかった。その他、胸部レントゲンではCTR47%で心拡大はなく、心臓、腎、頭部超音波検査では異常を認めなかった。

出生後10%グルコースにてグルコース注入速度(GIR)4.8mg/kg/minの糖補充を開始した。両親の承諾のもと出生後早期に遺伝子解析を実施したところ患児もE174K変異をヘテロでもつことが判明し、注意深い観察をおこなった。日齢1に10ml×8回/日から経管栄養を開始し、以後1回哺乳量を10mlずつ増量し、輸液は漸減していった。日齢5に経静脈栄養を中止し自律哺乳とした。

方 法

日齢1, 2, 3, 4, 5, 6, 7, 8, 14にろ紙血、血清を採取し、タンデムマスによるアシルカルニチン分析を島根大学において、既報の方法にて行った⁴⁾。

結 果

生後12時間(日齢1)での血液ろ紙のアシルカルニチンの結果は、C16は6.64μmol/L、C18:1は2.64μmol/L、C18は2.08μmol/Lと長鎖アシルカルニチンが高値であったがカットオフ値以下であった。しかし、(C18:1+C16)/C2は0.96とカットオフ値を超えて高




図2 血液ろ紙アシルカルニチンプロファイルの推移

上段の図では横軸は日齢、縦軸は各アシルカルニチン量。括弧内に上限または下限カットオフ値を示した。C16, C18, C18:1 はいずれも日齢3にピークとなり、その後漸減した。遊離カルニチンは明らかな低値を認めない。下段の図は (C16+C18:1)/C2 を縦軸に示した。図中にカットオフ値を直線で示した。出生直後が最も高く、日齢14まで上限値を超えている。




図3 血清アシルカルニチンプロファイルの推移

横軸は日齢、縦軸は各アシルカルニチン量。括弧内に上限または下限カットオフ値を示した。日齢1より明らかな長鎖アシルカルニチンの増加を認める。C16, C18, C18:1 は日齢4にピークとなりその後低下した。遊離カルニチンは明らかな低値を認めない。

値¹⁾であった(図1)。

血液ろ紙アシルカルニチンプロファイルの推移を示す(図2)。C16, C18, C18:1 はいずれも日齢3にピークとなり、その後漸減した。遊離カルニチンは日齢3に20.1μmol/Lまで上昇した後、若干の低下傾向を示したが、カットオフ値以下にはならなかった。CPT2欠損症のスクリーニング指標である(C16+C18:1)/C2の値の変化は、特に出生直後が最も高い結果となっており、以後徐々に低下しているが、日齢14まで上限

値を超えていた。

次に血清カルニチンのプロファイルを示す(図3)。日齢1の結果にて、C16は4.97μmol/L、C18:1は3.36μmol/L、C18は1.16μmol/Lと長鎖アシルカルニチンの増加が認められ、姉がCPT2欠損症と酵素診断されていることを考えてCPT2欠損症と化学診断した。血清C16, C18, C18:1は日齢4にピークとなりその後低下した。血清中遊離カルニチンは日齢4の39.87μmol/Lをピークに低下傾向となった。

考 察

CPT2欠損症では、血清中アシルカルニチン分画においてC2の低下、C16, C18, C18:1などの長鎖アシルカルニチンの上昇や(C16+C18:1)/C2の上昇をスクリーニング指標にして精査、診断に結びつける。

本症例における血液ろ紙ではC16, C18, C18:1の長鎖アシルカルニチンは日齢3にピークとなったが、上限カットオフ値をやや超える程度であった。しかし、血清中のC16, C18, C18:1は少なくとも日齢14まではカットオフ値を超えており、血清でのアシルカルニチン分析のほうが血液ろ紙に比較してより確実に異常を指摘できることが分かった。(C16+C18:1)/C2の値に関しては、血液ろ紙においては日齢14までカットオフ値を超えていた。血液ろ紙でスクリーニングを行う場合を行う場合、(C16+C18:1)/C2をより重視すべきであると考えられた。

遊離カルニチンは新生児期早期には低下を認めなかった。しかし、遊離カルニチンの低値を伴う二次性カルニチン欠乏が乳幼児発症型CPT2欠損症の患児でみられる²⁹⁾ため今後注意が必要である。患児の姉も発症時に遊離カルニチンの著明な低値を認めていた。

カルニチン欠乏がみられた場合はL-カルニチンの補充が重要である。また、カルニチン欠乏が明らかになる前に予防的な投与を考慮してもよいと思われる。

CPT2欠損症を含む先天代謝異常症のタンデムマススクリーニングは欧米をはじめとして各国で新生児マススクリーニングに導入されており、脂肪酸酸化異常症の早期発見に寄与している。血液ろ紙による新生児マススクリーニングの施行時期は、アメリカでは日齢1~2³⁰⁾に行われ、本邦におけるパイロットテストには日齢4~6のろ紙血が利用されている。本症例の結果では、血液ろ紙では長鎖アシルカルニチンのピークが日齢1~3にあり、その後減少していた。このことから日齢4~6に採取したろ紙血によるタンデムマススクリーニングでは、すでに長鎖アシルカルニチンは低下し始めており偽陰性となる可能性がある。そのため、本邦におけるスクリーニング採血時期を海外と同様にさらに早い時期に行う必要があるのではないかと考えられる。一方で血清アシルカルニチンではいずれの時期でもカットオフ値を超えていた。血液ろ紙分析でカットオフ値を超えていたC14:1アシルカルニチンが経過観察中にカットオフ値を下回った極長鎖アシル-CoA脱水素酵素欠損症症例が報告されており⁷⁾、スクリーニングの再検査や経過追跡には血清アシルカルニチン分析を行うことがよいと考えられる。

また、本症例においては出生時にCPT2欠損症を疑わせるような症状は認めなかったが、生後12時間後の

検体からすでにCPT2欠損症を示唆するアシルカルニチンプロファイルであった。特に本患者で同定されているCPT2遺伝子のE174K変異は、日本人成人型で同定された変異で、10%程度の残存活性を持っている変異である³¹⁾。母由来の変異は同定されていないが、少なくともCPT2の残存活性をもつために姉は新生児型でなく、乳幼児期発症型になったと考えられる。このような残存活性を持つ症例において、さらに持続的に糖補充をしていたにもかかわらず生後12時間からすでに血液ろ紙、血清のいずれにおいても異常が指摘された。

新生児早期からタンデムマス解析で異常を指摘できることから、新生児タンデムマススクリーニングの普及により、このような症例の発症前診断が可能となり、早期の治療的介入、指導により、発症の回避が可能になると思われた。

結 語

CPT2欠損症の血液ろ紙、血清のアシルカルニチンプロファイルの経時的変化を観察した。生後12時間後の検体からすでにCPT2欠損症を示唆するアシルカルニチンプロファイルであった。ろ紙による現行の採血時期におけるスクリーニングでは、すでにカットオフ値を下回っている可能性があり、スクリーニング時期をより早期に設定する必要があるのではないかと考えられた。

日本小児科学会の定める利益相反に関する開示事項はありません。

文 献

- 1) Shigematsu Y, Hirano S, Hata I, et al. Selective screening for fatty acid oxidation disorders by tandem mass spectrometry: difficulties in practical discrimination. *J Chromatogr B* 2003; 792: 63-72.
- 2) Bonnefont JP, Djouadi F, Prip-Buus C. Carnitine palmitoyltransferases 1 and 2: biochemical, molecular and medical aspects. *Mol Aspects Med* 2004; 25: 495-520.
- 3) Hori T, Fukao T, Kobayashi H, et al. Carnitine palmitoyltransferase 2 deficiency: the time-course of blood and urinary acylcarnitine levels during initial L-carnitine supplementation. *Tohoku J Exp Med* 2010; 221: 191-195.
- 4) Kobayashi H, Hasegawa Y, Endo M, et al. A retrospective ESI-MS/MS analysis of newborn blood spots from 18 symptomatic patients with organic acid and fatty acid oxidation disorders diagnosed either in infancy or in childhood. *J Inherit Metab Dis* 2007; 30: 606.
- 5) Longo N, Amat di San Filippo C, Pasquali M. Dis-

- orders of carnitine transport and the carnitine cycle. *Am J Med Genet C Semin Med Genet* 2006 ; 15 : 77—85.
- 6) Frazier DM, Millington DS, McCandless SE, et al. The tandem mass spectrometry newborn screening experience in North Carolina : 1997-2005. *J Inher Metab Dis* 2006 ; 29 : 76—85.
- 7) 虫木雄一, 小林弘典, 長谷川有紀, 他. 経過中血液ろ紙分析でカットオフ値を下回った極長鎖アシル-CoA 脱水素酵素欠損症の2例 : 血清分析の必要性. *日本マス・スクリーニング学会誌* 2009 ; 19 : 255—259.
- 8) Wataya K, Akanuma J, Cavadini P, et al. Two CPT2 mutations in three Japanese patients with carnitine palmitoyltransferase II deficiency : functional analysis and association with polymorphic haplotypes and two clinical phenotypes. *Hum Mutat* 1998 ; 11 : 377—386.

Carnitine Palmitoyltransferase-2 (CPT2) Deficiency : Time-dependent Changes of Acylcarnitine Profiles in Dried Blood Spots and Serum after Birth

Kazuo Kubota¹⁾, Toshiyuki Fukao²⁾, Tomohiro Hori¹⁾, Hironori Kobayashi³⁾,
Michinori Funato¹⁾, Yuki Hasegawa³⁾, Seiji Yamaguchi³⁾ and Naomi Kondo¹⁾

¹⁾Department of Pediatrics, Graduate School of Medicine, Gifu University

²⁾Medical Information Science Division, United Graduate School of Drug Discovery and Medical Information, Gifu University

³⁾Department of Pediatrics, Shimane University School of Medicine

We analyzed time-dependent changes of acylcarnitine profiles in dried blood spots and serum samples after birth in a CPT2-deficient patient. The boy was born at 37 weeks gestation via Caesarean section. Since his sister had CPT2 deficiency, he was carefully followed with intravenous glucose infusion from birth to day 6. Although he had no clinical symptoms, he was also diagnosed as CPT deficiency based on the family history and acylcarnitine analyses. In the acylcarnitine analyses using dried blood spots, peak levels of C16, C18, and C18 : 1 acylcarnitines, which are the usual screening markers for CPT2 deficiency, were above their upper cutoff values on day 3. However, their levels decreased and were under the cutoff values thereafter. The ratio C16 + C18 : 1/C2 was above the upper cutoff values until day 14, indicating that the ratio is a useful screening marker for CPT2 deficiency. In contrast, for acylcarnitine analyses using serum, although the peak levels of C16, C18, and C18 : 1 acylcarnitines were also detected on day 3, their levels declined gradually but still were above their upper cutoff values until day 14. These facts indicate that acylcarnitine analyses using serum detected this abnormality more effectively than using dried blood spots. Therefore, screening for fatty acid oxidation using dried blood spots on day 5 may result in a false-negative result since the values of C16, C18, and C18 : 1 acylcarnitines were under their cutoff values in our CPT2 deficient patient. Screening earlier than on day 5 may be considered to detect CPT2-deficient patients like this case.

小児の診療における尿ケトン

深尾 敏幸

岐阜大学大学院連合創薬医療情報研究科医療情報学専攻/
岐阜大学大学院医学系研究科小児病態学

尿ケトンの測定は小児科ではよく行われる検査である。発熱時や嘔吐下痢症などで尿ケトンを含めた尿試験紙検査をすることは、有意義であり、その点について述べたい。

ケトン体はグルコースをセーブするための代替エネルギー源であり、血糖の低下を防ぐために肝臓にて産生される。脂肪組織から動員された遊離脂肪酸をもとに肝臓のミトコンドリアで β 酸化を経てケトン体（アセト酢酸、3-ヒドロキシ酪酸）は産生され、血液中に放出される。これが血中ケトン体である。血中ケトン体は肝外組織に取り込まれ、再びアセチル-CoA となり、TCA サイクルに入ってエネルギーとなる。インスリンはこのケトン体産生を強く抑え、カテコールアミン、グルカゴンは促進する。このためインスリンが優位な食後や高インスリン血症ではケトン体産生は抑制され、カテコールアミン、グルカゴンは優位な空腹、感染、ストレスなどの状況ではケトン体産生は亢進する。このケトン体産生亢進は特に学童期以降に比べ乳幼児期で顕著である。血中のケトンが高くなると尿に排泄されるが、グルコースのような明らかな閾値は存在しない。尿試験紙法はアセト酢酸を検出しており、3-ヒドロキシ酪酸には反応しない。

尿ケトンの臨床的意味は以下のようである。通常尿ケトン陽性のほうが異常として注目されるが、

注意したいのは尿ケトン陰性の場合のほうである。

尿ケトン体強陽性であれば、飢餓やストレスに反応してケトン体産生の亢進状態で、少なくとも脂肪酸 β 酸化—ケトン体産生系は機能しており、長鎖脂肪酸代謝異常症やケトン体産生系異常症の可能性は少ないこと、そしてインスリン分泌亢進状態ではない（インスリン不足状態を含む）といえる。もちろん尿糖と尿ケトンがともに陽性であれば、糖尿病性ケトアシドーシスを疑わなくてはならない。

尿ケトン体陰性であれば、食事（糖分）がとれて、インスリンが機能していると一般には考えられるが、本来ケトン尿が有るべき飢餓、低血糖時であれば、インスリン過分泌、長鎖脂肪酸代謝異常症やケトン体産生系異常症を疑うことになる。


もし胃腸炎症状で、ぐったりして食事をとれていない児で、尿ケトンが強陽性（++～+++）であれば、むしろそれは当然であり、低血糖を防ぐためにケトン産生が亢進しているので、いちじるしい多呼吸や意識障害など重篤感がなければ、生理的反応といえる。低血糖のチェックとブドウ糖を含む輸液を考慮することが望ましい。いちじるしい多呼吸や意識障害など重篤感があれば、ケトアシドーシスが疑われ、さらなる精査加療を必要とする。一方この状態で尿ケトンが陰性であれば、むしろ異常であり、ケトン体産生に異常がある可能性が高い。すなわち脂肪酸 β 酸化やケトン体産生の異常を疑い、精査加療を必要とする。病歴や症状から、ケトン体強陽性になっておかしくない状況で陰性や弱陽性であるときに不自然だと感じられることが重要である。

また幼児期～10歳ごろまでは、いわゆる周期性嘔吐症という病態やケトン血性低血糖という病態があり、発作時尿ケトンは強陽性である。反復することが特徴であるが、一度は基礎疾患の有無について先天代謝異常症や内分泌の専門の小児科医にコンサルトしておくほうがよい。



Contents lists available at ScienceDirect

Molecular Genetics and Metabolism

journal homepage: www.elsevier.com/locate/ymgme

Clinical and molecular investigation of 19 Japanese cases of glutaric acidemia type 1

Yuichi Mushimoto*, Seiji Fukuda, Yuki Hasegawa, Hironori Kobayashi, Jamiyan Purevsuren, Hong Li, Takeshi Taketani, Seiji Yamaguchi

Department of Pediatrics, Shimane University Faculty of Medicine, Shimane, Japan

ARTICLE INFO

Article history:

Received 10 September 2010

Received in revised form 12 November 2010

Accepted 14 November 2010

Available online 25 November 2010

Keywords:

Glutaric acidemia type 1 (GA1)

Glutaryl-CoA dehydrogenase (GCDH)

Organic acidemia

Genotype-phenotype correlation

Common mutation

ABSTRACT

Glutaric acidemia type 1 (GA1) is a metabolic disease caused by a deficiency of glutaryl-CoA dehydrogenase (GCDH). Untreated patients mostly develop severe striatal degeneration. More than 200 mutations have been reported in the *GCDH* gene, and common R402W and IVS10-2A>C were found in Caucasian and Chinese/Taiwanese, respectively. However, in Japan, genetic mutations have only been reported in a few cases. Herein, we report the clinical and molecular basis of GA1 in 19 Japanese patients, including six previously reported patients. All cases showed high urinary glutaric acid excretion. Eleven patients were severely impaired (three patients died), three had mild impairment, and five showed normal development. Four of 5 patients that developed normally were detected in the presymptomatic stage by neonatal or sibling screening. Nineteen mutations in 26 alleles were identified, and eight of them (89 or 90delC, Y155C, IVS4+2T C, G244S, Q352X, G354A, K361E, and 1144-1145delGC) were novel. S305L (12.1%, 4/34 alleles) was found in several cases, suggesting that this mutation is a common mutation. In contrast, R402W was not identified and IVS10-2A>C was only found in one allele, suggesting that Japanese patients with GA1 show allelic heterogeneity and have a different genetic background to patients from other countries. One of a pair of sisters with the same mutations (M339V/S305L) lacking residual activity was severely retarded, whereas the older girl remains asymptomatic at 22 years of age, indicating that genotype does not necessarily predict GA1 phenotype. We consistently found that there was no association between genotype and phenotype. However, children with mild impairment were diagnosed and treated earlier than severely impaired cases (4.7 ± 2.5 months (range: 2–8 months) vs. 11.6 ± 12.7 months (range: 4–51 months)). Our results suggest that early detection and treatment but not genotype are associated with better patient outcome, reinforcing the importance of neonatal screening.

© 2010 Elsevier Inc. All rights reserved.

1. Introduction

Glutaric aciduria type 1 (GA1, OMIN 231670) is an autosomal recessive metabolic disorder caused by deficiency of glutaryl-CoA dehydrogenase (GCDH, EC 1.3.99.7) [1,2]. GCDH is located in the mitochondrial matrix and acts in the intermediate steps of lysine, hydroxylysine, and tryptophan metabolisms [3]. The clinical manifestations of GA1 include extrapyramidal symptoms, developmental regression, and macrocephaly, appearing most often after acute encephalopathic crises, which are accompanied by bilateral marked enlargement of the sylvian fissure and degeneration of the striatum [1], and in addition, extrastriatal abnormalities [4] and abnormal hemodynamic changes [5]. Its biochemical characteristics include the accumulation of glutaric acid (GA), and 3-hydroxyglutaric acid, which can be detected by gas chromatography (GC/MS), and glutarylcarnitine, which can be identified by electrospray ionization/tandem mass spectrometry (MS/MS) [1,2]. It has been reported that GA1 can be classified into two types based on the level of excreted GA: the high

excretion form (GA > 100 mmol/mol creatine) and the low excretion form (GA < 100 mmol/mol creatine) [6].

Since GA1 was first described in 1975 [3], more than 200 different mutations have been reported [7–9], and its frequency was estimated to be approximately 1 in 100,000 newborns [2]. Although almost all mutations are private, several common mutations have been identified, including A421V in the Amish Community [10], IVS 1+5G T in Canadian Oji-Cree Indians [11], and E365K in Irish travelers [8]. R402W is the most frequent mutation in the European population [6,8], and IVS10-2A C is relatively common in China [12] and Taiwan [13]. In Japan, the frequency of GA1 has been estimated to be approximately 1 in 210,000 newborns, based on a newborn screening pilot study [14,15]. However, mutations have only been characterized in a few cases [16] since the first description of a Japanese case in 1987 [17]. Herein, we investigated the clinical and molecular aspects of 19 Japanese patients with GA1.

2. Subjects and methods

2.1. Subjects

We studied 19 Japanese patients who were diagnosed with GA1 based on their urinary organic acid profiles and/or blood acylcarnitine

* Corresponding author. Department of Pediatrics, Shimane University Faculty of Medicine, 89-1 Enya, Izumo, Shimane 693-8501, Japan. Fax: +81 85 320 2215.

E-mail address: mushiu1@med.shimane-u.ac.jp (Y. Mushimoto).

analysis. The diagnoses were confirmed by analyzing the *GCDH* gene and/or *GCDH* activity.

The mutations of 6 cases (cases 2–5, 12, and 19) were reported previously (cases 4, 12, and 19: [16], cases 2, 3, and 5: Japanese domestic journal). In this study, we analyzed the mutations in 13 cases (cases 1, 6–11, and 13–18). Among the 13 patients, 4 cases (case 6, 7, 10, and 11) were previously described in case reports [18,19]. No family demonstrated consanguineous marriage.

2.2. DNA sequencing

Genomic DNA was isolated from skin fibroblasts using a Qiam DNA Microkit (QIAGEN GmbH, Hilden, Germany) and from peripheral blood lymphocytes using the DNA Quick II kit (Dainippon Pharmaceuticals, Osaka, Japan). Each exon of *GCDH* including the intron/exon boundaries was PCR-amplified for 30 cycles using the conditions shown in Supplemental Table 1. The PCR products were purified using a QIAquick PCR Purification Kit (QIAGEN GmbH, Hilden, Germany) and sequenced using the ABI PRISM 310 Genetic Analyzer (PE Applied Biosystems, Foster City, CA, USA) or the CEQ 8000 Genetic Analysis System (Beckman Coulter Inc., Fullerton, CA, USA). The structure of the human *GCDH* gene was obtained from the GenBank database (ENSG00000105607). Informed consent to perform DNA analysis was obtained from the parents of the patients. Our study protocol was approved by the Ethics Committee of the Shimane University Faculty of Medicine.

3. Results

3.1. Clinical characteristics

The clinical features of 19 Japanese GA1 patients (10 boys and 9 girls) are summarized in Table 1. Cases 4 and 19 and cases 15 and 18 were siblings. Fifteen of the 19 cases were symptomatic patients. Three (cases 1–3) of 19 cases were detected in a newborn screening pilot study, and one (case 4) was an asymptomatic sibling case that was detected at 2 years of age. To evaluate their outcomes, we classified them into three groups based on disability score [20] that included motor disability, cognitive function, and speech: a) the severe handicap group (disability score 7–9), b) the mild impairment group (disability score 4–6), and c) the normal developmental group (disability score 3) (Supplemental Table 2).

Eleven of the 19 cases were classified into severe handicap group (three of them died), 3 cases belonged to mild impairment group, and 5 cases showed normal development (Fig. 1). The mean age at onset of the symptomatic cases was 5.7 m (range: 4–8 m) in the severe handicap group, 2.3 m (range: 2–3 m) in the mild impairment group, and 6 m in case 4 of the normal development group who suffered from macrocephaly. The mean age at diagnosis was 11.6 m (range: 4–51 m) in the severe handicap group, 4.7 m (range: 2–8 m) in the mild impairment group, and 27 m (range: 24–30 m) in the normal development group, except for the 3 cases diagnosed by newborn screening. Macrocephaly was observed in 31.6% of patients (6/19). All 19 cases showed high urinary glutaric acid excretion. Cranial CT and/or MRI demonstrated frontotemporal atrophy and striatum signal abnormalities in all cases involving mild impairment or severe handicap. In contrast, three of five cases in the normal development group demonstrated mild changes by neuroimaging.

3.2. Clinical manifestations of patients

No cases had a past history except for cases 1, 6, 7, and 9. None of the cases showed abnormal development before the onset of GA1. Immediately after the diagnosis of GA1, all cases were treated with dietary restriction, L-carnitine administration, and prompt intravenous fluid infusions for catabolic states such as recurrent vomiting and

diarrhea. In addition, a GABA analogue and vitamin B2 were given to the 14 and 8 cases, respectively.

3.2.1. Normal development group

Cases 1–3 were detected prior to displaying any specific symptoms by a newborn screening program using MS/MS. Case 1 weighed 2952 g when she was born at a gestational age of 39 weeks and 2 days. Abruptio placentae occurred during her birth and she suffered from asphyxia (Apgar score: 3/4). She recovered following hypothermia treatment for hypoxic–ischemic encephalopathy. Cases 2 [21] and 3 [21] had no remarkable delivery events. In these 3 cases, no signs of neurologic complications were evident at 4 months, 5 years, and 7 years old, respectively.

Case 4 was the nonsymptomatic older sister of case 19, who was severely handicapped [16]. She was diagnosed with GA1 by a sibling GC/MS screening in the presymptomatic stage at 2 years old.

Case 5 was hospitalized because of macrocephaly (47.6 cm, +2.5 S.D.) at 6 months. There was no sign of neurologic complications or developmental delay, but cranial CT suggested a subarachnoid cyst and a subdural hematoma. Thereafter, the subarachnoid cyst and subdural hematoma became smaller. At 2.5 years, he was referred to the pediatric department due to progressive macrocephaly (56.5 cm, +3.0 S.D.). Brain CT demonstrated widening of the Sylvian fissures, which in fact had been found by CT at 7 months.

3.2.2. Mild impairment group

Case 6 was treated for initial vomiting and idiopathic hyperbilirubinemia during the neonatal period [18]. Screening by brain echography identified dilated ventricles.

Case 7 was delivered at 27 weeks of dizygotic twin gestation [18]. His birth weight was 998 g. Macrocephaly and convulsions were noticed at 2 and 3 months, respectively. Following treatment, his development caught up.

In case 8, progressive macrocephaly was noticed at 3 months old. Her head circumference was +5.0 S.D. at 7 months old. Her regression and hypotonia, which were accompanied by seizures at 8 months old, improved gradually after treatment.

3.2.3. Severe handicap group

Cases 10, 11, and 13 died. Case 10 displayed a lack of head control at 4 months old [17,18] and irritability and sleeplessness at 5 months old. She died suddenly at 5 years old after developing a common cold. Cases 11 [19] and 13 presented encephalitis-like disease at 5 and 7 months, respectively. Case 11 died suddenly at the age of 3 years. Case 13 died of airway obstruction due to choking after developing an infection at 3 years old.

Similarly, no treatment was effective for the neurological symptoms of the severely handicapped patients that survived, all of whom are bedridden, require tube feeding, and smile spontaneously. Case 9 was born at 35 weeks with an Apgar score of 6/9 by cesarean delivery for premature membrane rupture and breech presentation. His birth weight was 2235 g. He was diagnosed with GA1 at 4 months after an episode of convulsions. He required mechanical ventilation and a tracheostomy for respiratory distress at 10 months old. Case 12 suffered from encephalitis-like symptoms including convulsions, unconsciousness, and rigidity following fever and an upper respiratory tract infection at 5 months old [16]. Case 14 was affected with Kawasaki disease at 5 months old. Intravenous immunoglobulin resulted in rapid defervescence, but his regression, involuntary movement, and irritability accompanied by fever were irreversible. Case 16 was affected by viral encephalitis with hyperpyrexia, consciousness disturbance, and hypertonia at 7 months of age. Case 17 was found to have subependymal pseudocysts and temporal lobe hypoplasia at 1 month. Transient regression was observed at 7 months after gastroenteritis. Thereafter, progressive neurological regression, hypotonia, and rigidity were observed following convulsions associated with pneumonia at 8 months. Case 19 was the younger sister of

Table 1

Clinical manifestations and genetic characteristics of Japanese patients with glutaric acidemia type 1.

Case I.D	Sex	Age at onset	Age at diagnosis	Precipitating factor	Clinical symptoms	Macrocephaly	Treatment	Outcome	Urine GA	C5DC (<0.3)	Neuroimaging	Exon or intron affected	Base change	Effect	GCDH activity
<i>Normal development group (Newborn screening cases)</i>															
1	F	—	1m	None	Normal development	—	L-carnitine	Normal (4m)	High	1.08	Typical	Exon9 / Exon10	1064 G>A / 1147 C>T	R355H/R383C	N.D
2	F	—	1 m	None	Normal development	—	L-carnitine	Normal (5y4m)	High	2.22	Mild	Exon6 / Exon8	556 A>T / 914 C>T	S186C / S305L	Deficiency
3	F	—	1 m	None	Normal development	—	L-carnitine	Normal (7y6m)	High	1.95	Mild	Exon3 / Exon10	215 G>T / 1237 T>G	R72L / Y413D	Deficiency
<i>(Sibling screening cases)</i>															
a 4	F	—	2 y 0 m	None	Normal development	—	L-carnitine, GABA analogue	Normal (22y)	High	N.D	Mild	Exon8 / Exon9	914C>T / 1015A>G	S305L / M339V	Deficiency
<i>(other cases except for screening)</i>															
5	M	6	2 y 6 m	None	Normal development	+	L-carnitine, vitamin B2	Normal (6y11m)	High	4.4	Typical	Exon5 / ?	416C>T / ?	S139L / ?	Deficiency
<i>Mild impairment group</i>															
6	M	2 m	2 m	None	Enlargement of ventricles	+	L-carnitine, vitamin B2, GABA analogue	Mild (23y)	High	N.D	Typical	Exon8 / Exon10	914C>T / 1147 C>T	S305L / R383C	Deficiency
7	M	2 m	4 m	None	Seizure	+	L-carnitine, GABA analogue	Mild (25y)	High	N.D	Typical	Exon5 / Exon5	413G>A / 416C>T	R138K / S139L	Deficiency
8	F	3 m	8 m	None	Seizure, regression	+	L-carnitine, GABA analogue, antiepileptic	Mild (3y2m)	High	3.36	Typical	Exon8/ Exon9	914C>T / 1081A>G	S305L / K361E	N.D
<i>Severe handicap group</i>															
9	M	4 m	4 m	None	Seizure, regression	+	L-carnitine, vitamin B2, antiepileptic	Severe (1y4m)	High	N.D	Typical	Intron4 / Exon6	<u>IVS4+2T>C / 532G>A</u>	<u>Truncated (Splicing) / G178R</u>	N.D
10	F	4 m	7 m	None	Regression, irritability, sleeplessness, dystonia	—	L-carnitine, vitamin B2, GABA analogue	Severe (5y;died)	High	N.D	Typical	Exon9 / Exon9	<u>1054C>T / 1054C>T</u>	<u>Truncated(Q352stop) / Truncated(Q352stop)</u>	Deficiency
11	M	5 m	6 m	None	Seizure, regression, hypotonia, dystonia	—	L-carnitine, GABA analogue	Severe (3y;died)	High	N.D	Typical	Exon3 / Exon7	<u>226C>T / 730G>A</u>	<u>Truncated (Q76stop) / G244S</u>	Deficiency
12	M	5 m	6 m	Infection, fever	Seizure, dystonic	—	L-carnitine, vitamin B2, GABA analogue	Severe (14y6m)	High	N.D	Typical	Exon9 / Exon9	1064G>A / 1064G>A	R355H / R355H	N.D
13	F	5 m	7 m	Infection	Seizure, regression, hypertonia	—	L-carnitine, GABA analogue	Severe (3y9m; died)	High	N.D	Typical	Exon9 / Intron10	<u>1061G>C / IVS10-2 A>C</u>	<u>G354A / Truncated (splicing)</u>	Deficiency
14	M	5 m	7 m	Kawasaki disease	Regression, dystonia	—	L-carnitine, GABA analogue, antiepileptic	Severe (7y)	High	1.76	Typical	Exon5 / Exon7	416C>T / 769C>T	S139L / R257W	Deficiency
b 15	M	5 m	4 y 3 m	Fever of unknown origin	Regression, dystonia	—	L-carnitine, vitamin B2, GABA analogue	Severe (5y2m)	High	0.38	Typical	Exon1 / Exon5	<u>89 or 90delC / 461A>G</u>	<u>Truncated (frame shift) / Y155C</u>	N.D
16	M	7 m	7 m	Infection, fever	Unconscious, dystonia	—	L-carnitine, GABA analogue	Severe (1y1m)	High	0.57	Typical	Exon10 / Exon11	<u>1144-1145delGC / 1298C>T</u>	<u>Truncated (frame shift) / A433V</u>	N.D
17	M	7 m	12 m	Gastroenteritis	Seizure, regression, dystonia, hypotonia	+	L-carnitine, GABA analogue, antiepileptic	Severe (2y5m)	High	N.D	Typical	Exon5 / Exon10	<u>383G>A / 1147C>T</u>	<u>R128Q / R383C</u>	Deficiency
b 18	F	8 m	9 m	Polio vaccine, infection, fever	Regression, dystonia	—	L-carnitine, vitamin B2, GABA analogue	Severe (1y8m)	High	0.41	Typical	Exon1 / Exon5	<u>89 or 90delC / 461A>G</u>	<u>Truncated (frame shift) / Y155C</u>	Deficiency
a 19	F	8 m	12 m	Gastroenteritis	Coma, dystonia	—	L-carnitine, vitamin B2, GABA analogue	Severe (20y)	High	N.D	Typical	Exon8 / Exon9	914C>T / 1015A>G	S305L / M339V	Deficiency

Abbreviations: a,b, siblings; M, male; F, female; Age, y (years); m (months); Treatment, except for dietary restriction ; GA, glutaric acid; C5DC, glutaryl-carnitine in dried spots (nmol/ml) when the patient was diagnosed; GCDH, glutaryl-CoA dehydrogenase.

Novel mutations are underlined. The mutations highlighted in bold were identified in this study; Deficiency: GCDH activity $\leq 5\%$.

N.D: not determined.




Fig. 1. Age at onset and diagnosis in three groups with different outcomes. The mild impairment group was diagnosed earlier than the severe handicap group (4.7 m (2–8 m) vs. 11.6 m (4–51 m)). Three cases (cases 10, 11, and 13) died.

case 4. At 8 months old, she suffered an encephalopathic crisis after gastroenteritis, which lasted for several days [16]. Cases 15 and 18 were siblings. Case 15, the older brother, was hospitalized for fever of unknown origin at 5 months of age and treated with antibiotics for 10 days. In addition to hypotonia, which appeared at the time of discharge, his regression, rigidity, and involuntary movement worsened every month that he suffered from fever. Although idiopathic encephalopathy was initially suspected, a diagnosis of GA1 was made in a sibling screening program by GC/MS, and treatment was initiated at 4 years and 3 months. Case 18 suffered from fever after polio vaccination at 8 months. Thereafter, she became unable to support her head and roll over. Her neurological skills deteriorated every month that she suffered from fever. The diagnosis of GA1 was made by GC/MS at 9 months of age.

3.3. Gene mutations in GCDH

Nineteen mutations were identified in 13 cases, and 8 of them were novel. These included four missense mutations (Y155C, G244S, G354A, and K361E), a nonsense change (Q352X), a splice site alteration (IVS4+2T>C), and frame shift mutations (89 or 90delC, and 1144–1145delGC). These novel mutations were not detected in 100 chromosomes from unaffected Japanese individuals.

All mutations are summarized in Table 1 and Supplemental Fig. 1, together with information on 6 cases whose genetic alterations were reported previously ([16] and Japanese domestic journal). Only two unrelated patients out of 19 cases had homozygous mutations (Q352X, R355H). In 34 independent alleles, the frequency of S305L was 12.1% (4/34 alleles), S139L, R355H, and R383C had frequencies of 8.8% (3/34 alleles), respectively and Q352X were found in 2 alleles (5.8%) each. Another 19 mutations were only found in a single allele.

4. Discussion

Since it has been remaining unknown whether there are common mutations and a phenotype/genotype correlation in Japanese GA1

cases, we investigated the relationship between clinical and mutational spectrums of 19 Japanese patients with GA1. Japanese are relatively homogenous ethnic population on islands isolated from other countries. We found a few common mutations distinct from other nations. We also found that mutations in Japanese cases are different from what have been reported in the Caucasian cases, indicating specific genetic information unique for Japanese cases are crucial for their diagnosis in the future. The current study also indicates that earlier detection of the disease followed by appropriate medicare is crucial for the better outcome than the genotype, reinforcing the importance of neonatal screening for GA1. This is a first report that studied the largest cohort of Japanese patients with GA1.

In this study, we identified 19 mutations in 24 independent alleles including eight novel mutations. The amino acids affected by these new mutations are highly conserved among different species (Pan troglodytes, mice, Xenopus, and Bordetella parapertusis) including humans, suggesting that the region plays an important functional role in GCDH activity. It is highly likely that Q352X, 89 or 90 delC, 1144–1145delGC, and IVS4+2T C abolish GCDH activity, because these mutations result in truncation of the peptide. G354S and Y155H, which affect the same positions as G354A and Y155C, respectively, were reported to have no enzymatic activity [6,7]. The homology of the peptide's structure indicates that G244, G354, and K361 are conserved in the acyl-CoA dehydrogenase group [22]. These findings suggested that all 8 novel mutations in this study have little GCDH activity. In the 19 Japanese cases of GA1 including 6 previously reported patients, Q352X and R355H were homozygous mutations and found in 2 alleles. The frequency of S305L was 12.1% (4/34 alleles), suggesting that this mutation is common in Japanese, in contrast to the very few reports of this mutation from other countries. S139L, R355H, and R383C were also found on 8.8% (3/34 alleles), respectively, implicating that these mutations may be also common, respectively. Additionally, mutations in exon 9 were found more frequently in Japanese GA1 compared with the report by the HGMD (<http://www.hgmd.cf.ac.uk/ac/index.php>). It is highly likely that understanding common mutations

will facilitate rapid and accurate diagnosis of Japanese cases with GA1. Furthermore, this information may be useful for other Asian countries as well, since some of them are shared with patients from other Asian countries. Newborn screening using MS/MS is becoming popular, and the number of patients will become larger in Asian countries [23] as well as the other countries [24–26]. R402W, the most common mutation in Caucasians, in whom it shows an allele frequency of 12–25% [6,8], was not found in our Japanese cases. IVS10-2A C, a common mutation in China (30%, 3/10 alleles) [10] and Taiwan (66.7%, 4/6 alleles) [13], was also only found in a single allele in our study. Collectively, these findings suggest that Japanese GA1 patients show allelic heterogeneity and have different genetic backgrounds to GA1 patients from other countries. However, S139L, R355H and G178R, in addition to IVS10-2A C, may be common mutations among oriental populations, since S139L have been discovered in 2 of 4 alleles in Korean cases [27], and R355H and G178R were detected in one allele in Chinese case, respectively [10].

All 19 cases demonstrated a high-excretor phenotype in urinary organic acid analysis by GC/MS, suggesting that their mutations resulted in lower enzyme activity ($\leq 5\%$) [6]. In fact, an enzyme assay confirmed 0–5% residual GCDH activity in 11 cases (Cases 2–7, 10–11, 13–14, and 19) [19,21,28,29]. Furthermore, an *in vitro* probe assay using cultured fibroblasts and MS/MS demonstrated a deficiency of GCDH in 10 cases (cases 4, 6, 7, 10, 11, 13–14, and 17–19) [30]. Although all 19 cases were assumed to have barely detectable enzyme activity, their clinical outcomes were diverse, ranging from normal development, through mild impairment, to severe handicap. This study suggests that the phenotypes of Japanese GA1 patients are not associated with a specific genotype. A previous study also showed that there is no clear correlation between genotype, biochemical phenotype, and the clinical severity of GA1 [6,24]. Frequency (31.6%: 6/19 cases) of macrocephaly of this study is lower than other reports (65–75%) [2,31]. This may represent unique phenotype in Japanese patients with GA1, which have genetic backgrounds distinct from other nations. However, additional case studies are warranted to validate whether this is indeed the cases.

All symptomatic cases except for case 5 had mild impairment or severe handicap indicating that the neurological sequelae of symptomatic cases are poor in Japanese GA1 patients, as reported in previous cases [24,31–33]. With respect to the grounds for the neurological manifestation, we were not able to completely rule out hypoxic–ischemic encephalopathy, hyperbilirubinemia, prematurity, very low birth weight, or encephalitis. However, since there was no sign of neurologic complications or developmental delay before the onset in any cases, we suspect that the neurological symptoms are not a consequence of these conditions. Importantly, the mild impairment group was diagnosed earlier than the severe handicap group (4.7 ± 2.5 m (2–8 m) vs. 11.6 ± 12.7 m (4–51 m)), suggesting that a better outcome was induced by early diagnosis. The reason for the better outcome seen in the patients who were diagnosed younger age was considered that early diagnosis led to an earlier initiation of the treatment and/or intervention in a timely manner for any medical conditions, which in turn prevented patients from neurological impairment. The frequency of macrocephaly was higher in the mild impairment group (3/3 cases) than in the severe impairment group (2/11 cases), making it likely that macrocephaly led to an early diagnosis of GA1. Furthermore, there was a notable difference in the phenotypes of siblings with the same mutations: case 4 showed normal development, whereas case 19 showed severe retardation (Supplemental Fig. 2), indicating that genotype does not predict clinical outcome. Taken together, these findings strongly suggest that early diagnosis and treatment but not genotype are associated with a better patient outcome.

Because the diagnosis was made by newborn screening only in 15.8% (3/19 cases), there is no direct evidence that newborn screening has neuroprotective effect for the patients with GA1 in this study. However, our study indicates that genotype does not necessarily predict clinical outcome and that early diagnosis and treatment are critical for a better outcome. While indirect findings, these observations strongly suggest

that earliest diagnosis by the newborn screening will also be beneficial for a better outcome. In this regard, it is very important to expand newborn screening by MS/MS to improve the outcome of Japanese GA1 patients.

Supplementary materials related to this article can be found online at doi:10.1016/j.ymgme.2010.11.159.

Acknowledgments

We thank the attending physicians in charge of the present cases for providing clinical information regarding each patient. We are also grateful to Nana Tomita, Mayumi Nagase, Mayumi Naito, Midori Furui, Rie Eda, Toyomi Esumi, Yuka Ito, and Shine Mushimoto for their technical assistance. This study was partly supported by grants from The Ministry of Health, Labor, and Welfare of Japan and from the Ministry of Education, Culture, Sports, Science, and Technology.

References

- [1] F.F. Goodman SI, Organic acidemias due to defects in lysine oxidation: 2-ketoadipic academia and glutaric acidemia, in: e.a. Scriver C (Ed.), *Mol Met Basis Inher Dis*, McGraw-Hill Inc, New York, 2001, pp. 2195–2204.
- [2] S. Kolker, E. Christensen, J.V. Leonard, C.R. Greenberg, A.B. Burlina, A.P. Burlina, M. Dixon, M. Duran, S.I. Goodman, D.M. Koeller, E. Muller, E.R. Naughten, E. Neumaier-Probst, J.G. Okun, M. Kyllerman, R.A. Surtees, B. Wilcken, G.F. Hoffmann, P. Burgard, Guideline for the diagnosis and management of glutaryl-CoA dehydrogenase deficiency (glutaric aciduria type I), *J. Inher. Metab. Dis.* 30 (2007) 5–22.
- [3] S.I. Goodman, S.P. Markey, P.G. Moe, B.S. Miles, C.C. Teng, Glutaric aciduria: a “new” disorder of amino acid metabolism, *Biochem. Med.* 12 (1975) 12–21.
- [4] I. Harting, E. Neumaier-Probst, A. Seitz, E.M. Maier, B. Assmann, I. Baric, M. Troncoso, C. Muhlhäuser, J. Zschocke, N.P. Boy, G.F. Hoffmann, S.F. Garbade, S. Kolker, Dynamic changes of striatal and extrastriatal abnormalities in glutaric aciduria type I, *Brain* 132 (2009) 1764–1782.
- [5] K.A. Strauss, P. Donnelly, M. Wintermark, Cerebral haemodynamics in patients with glutaryl-coenzyme A dehydrogenase deficiency, *Brain* 133 (2010) 76–92.
- [6] E. Christensen, A. Ribes, B. Merinero, J. Zschocke, Correlation of genotype and phenotype in glutaryl-CoA dehydrogenase deficiency, *J. Inher. Metab. Dis.* 27 (2004) 861–868.
- [7] S.I. Goodman, D.E. Stein, S. Schlesinger, E. Christensen, M. Schwartz, C.R. Greenberg, O.N. Elpeleg, Glutaryl-CoA dehydrogenase mutations in glutaric acidemia (type I): review and report of thirty novel mutations, *Hum. Mutat.* 12 (1998) 141–144.
- [8] J. Zschocke, E. Quak, P. Guldberg, G.F. Hoffmann, Mutation analysis in glutaric aciduria type I, *J. Med. Genet.* 37 (2000) 177–181.
- [9] M. Schwartz, E. Christensen, A. Superti-Furga, N.J. Brandt, The human glutaryl-CoA dehydrogenase gene: report of intronic sequences and of 13 novel mutations causing glutaric aciduria type I, *Hum. Genet.* 102 (1998) 452–458.
- [10] B.J. Biery, D.E. Stein, D.H. Morton, S.I. Goodman, Gene structure and mutations of glutaryl-coenzyme A dehydrogenase: impaired association of enzyme subunits that is due to an A421V substitution causes glutaric acidemia type I in the Amish, *Am. J. Hum. Genet.* 59 (1996) 1006–1011.
- [11] C.R. Greenberg, D. Reimer, R. Singal, B. Triggs-Raine, A.E. Chudley, L.A. Dilling, S. Philipps, J.C. Haworth, L.E. Seargeant, S.I. Goodman, A G-to-T transversion at the +5 position of intron 1 in the glutaryl CoA dehydrogenase gene is associated with the Island Lake variant of glutaric acidemia type I, *Hum. Mol. Genet.* 4 (1995) 493–495.
- [12] N.L. Tang, J. Hui, L.K. Law, Y.Y. Lam, K.Y. Chan, W.L. Yeung, A.Y. Chan, K.L. Cheung, T.F. Fok, Recurrent and novel mutations of GCDH gene in Chinese glutaric acidemia type I families, *Hum. Mutat.* 16 (2000) 446.
- [13] S.G. Shu, C.R. Tsai, L.H. Chen, C.S. Chi, Type I glutaric aciduria: phenotypes and genotypes in 5 Taiwanese children, *J. Formos. Med. Assoc.* 102 (2003) 729–732.
- [14] Y. Shigematsu, S. Hirano, I. Hata, Y. Tanaka, M. Sudo, N. Sakura, T. Tajima, S. Yamaguchi, Newborn mass screening and selective screening using electrospray tandem mass spectrometry in Japan, *J. Chromatogr. B* 776 (2002) 39–48.
- [15] Y. Shigematsu, I. Hata, *Jpn J. Pediatr. Med.* 42 (2010) 1200–1204, (in Japanese).
- [16] H. Ikeda, T. Kimura, T. Ikegami, M. Kato, A. Matsunaga, S. Yokoyama, S. Yamaguchi, T. Ohura, K. Hayasaka, Novel mutations of the glutaryl-CoA dehydrogenase gene in two Japanese patients with glutaric aciduria type I, *Am. J. Med. Genet.* 80 (1998) 327–329.
- [17] S. Yamaguchi, T. Orii, K. Yasuda, Y. Kohno, A case of glutaric aciduria type I with unique abnormalities in the cerebral CT findings, *Tohoku J. Exp. Med.* 151 (1987) 293–299.
- [18] H. Nagasawa, S. Yamaguchi, Y. Suzuki, M. Kobayashi, Y. Wada, K. Shikura, S. Shimao, T. Okada, T. Orii, Neuroradiological findings in glutaric aciduria type I: report of four Japanese patients, *Acta Paediatr. Jpn* 34 (1992) 409–415, (Overseas edition).
- [19] H. Osaka, S. Kimura, A. Nezu, S. Yamazaki, K. Saitoh, S. Yamaguchi, Chronic subdural hematoma, as an initial manifestation of glutaric aciduria type-1, *Brain Dev.* 15 (1993) 125–127.
- [20] M. Kyllerman, O. Skjeldal, E. Christensen, G. Hagberg, E. Holme, T. Lonnquist, L. Skov, T. Rotwelt, U. von Döbeln, Long-term follow-up, neurological outcome and survival rate in 28 Nordic patients with glutaric aciduria type 1, *Eur. J. Paediatr. Neurol.* 8 (2004) 121–129.
- [21] Y. Shigematsu, I. Hata, Y. Tanaka, G. Tajima, N. Sakura, E. Naito, T. Yorifuji, Stable-isotope dilution gas chromatography-mass spectrometric measurement of 3-hydroxyglutaric

- acid, glutaric acid and related metabolites in body fluids of patients with glutaric aciduria type 1 found in newborn screening, *J. Chromatogr. B* 823 (2005) 7–12.
- [22] Z. Fu, M. Wang, R. Paschke, K.S. Rao, F.E. Frerman, J.J. Kim, Crystal structures of human glutaryl-CoA dehydrogenase with and without an alternate substrate: structural bases of dehydrogenation and decarboxylation reactions, *Biochemistry (Mosc)* 43 (2004) 9674–9684.
- [23] C.T. Hsieh, W.L. Hwu, Y.T. Huang, A.C. Huang, S.F. Wang, M.H. Hu, Y.H. Chien, Early detection of glutaric aciduria type I by newborn screening in Taiwan, *J. Formos. Med. Assoc.* 107 (2008) 139–144.
- [24] S. Kolker, S.F. Garbade, C.R. Greenberg, J.V. Leonard, J.M. Saudubray, A. Ribes, H.S. Kalkanoglu, A.M. Lund, B. Merinero, M. Wajner, M. Troncoso, M. Williams, J.H. Walter, J. Campistol, M. Marti-Herrero, M. Caswill, A.B. Burlina, F. Lagler, E.M. Maier, B. Schwahn, A. Tokatli, A. Dursun, T. Coskun, R.A. Chalmers, D.M. Koeller, J. Zschocke, E. Christensen, P. Burgard, G.F. Hoffmann, Natural history, outcome, and treatment efficacy in children and adults with glutaryl-CoA dehydrogenase deficiency, *Pediatr. Res.* 59 (2006) 840–847.
- [25] S. Kolker, S.F. Garbade, N. Boy, E.M. Maier, T. Meissner, C. Muhlhause, J.B. Hennermann, T. Lucke, J. Haberle, J. Baumkotter, W. Haller, E. Muller, J. Zschocke, P. Burgard, G.F. Hoffmann, Decline of acute encephalopathic crises in children with glutaryl-CoA dehydrogenase deficiency identified by newborn screening in Germany, *Pediatr. Res.* 62 (2007) 357–363.
- [26] S. Bijarnia, V. Wiley, K. Carpenter, J. Christodoulou, C.J. Ellaway, B. Wilcken, Glutaric aciduria type I: outcome following detection by newborn screening, *J. Inherit. Metab. Dis.* 31 (2008) 503–507.
- [27] J.D. Park, B. Lim, K.J. Kim, Y.S. Hwang, S.K. Kim, S.H. Kang, S.I. Cho, S.S. Park, J.S. Lee, J.H. Chae, Glutaric aciduria type 1 in Korea: report of two novel mutations, *J. Korean Med. Sci.* 25 (2010) 957–960.
- [28] S. Kubo, T. Ariga, T. Okayasu, S. Arashima, K. Yuri, M. Nakayama, T. Ishii, A. Yamaguchi, Y. Kusunoki, S. Yamaguchi, Two siblings with glutaric acidemia type1, *J. Jpn. Pediatr. Soc.* 96 (1992) 2545–2549.
- [29] H. Nagasawa, S. Yamaguchi, T. Orii, M. Kobayashi, Y. Wada, K. Shikura, S. Shimao, T. Okada, Glutaric aciduria type1: four Japanese cases and their family investigation, *J. Jpn. Pediatr. Society.* 94 (1990) 103–1808.
- [30] Y. Mushimoto, Y. Hasegawa, H. Kobayashi, H. Li, J. Purevsuren, I. Nakamura, T. Taketani, S. Fukuda, S. Yamaguchi, Enzymatic evaluation of glutaric acidemia type 1 by an in vitro probe assay of acylcarnitine profiling using fibroblasts and electrospray ionization/tandem mass spectrometry (MS/MS), *J. Chromatogr. B* 877 (2009) 2648–2651.
- [31] K.B. Bjugstad, S.I. Goodman, C.R. Freed, Age at symptom onset predicts severity of motor impairment and clinical outcome of glutaric acidemia type 1, *J. Pediatr.* 137 (2000) 681–686.
- [32] G.F. Hoffmann, H.J. Bohles, A. Burlina, M. Duran, J. Herwig, W. Lehnert, J.V. Leonard, A. Muntau, F.K. Plecko-Starting, A. Superti-Furga, Early signs and course of disease of glutaryl-CoA dehydrogenase deficiency, *J. Inherit. Metab. Dis.* 18 (1995) 173–176.
- [33] K.A. Strauss, E.G. Puffenberger, D.L. Robinson, D.H. Morton, Type 1 glutaric aciduria, part 1: natural history of 77 patients, *Am. J. Med. Genet. C Semin. Med. Genet.* 121 (2003) 38–52.

新生児マス・スクリーニング検査施設基準 日本マス・スクリーニング学会制定 (2010年3月)

学会理事長

山口清次

技術システム検討委員会担当理事

重松陽介, 河地 豊, 福士 勝

1. 趣 旨

新生児マス・スクリーニング検査（以下、スクリーニング検査）は、大多数が正常な検体の中から、疑わしい検体を正確に見つけ出さなければならない。このため、新生児マス・スクリーニング検査施設（以下、検査施設）には、一般臨床検査と異なり、スクリーニング検査に関連する専門的な知識と技術に基づいて正常か否かの難しい判断をすることが要求される。そこで、スクリーニング検査が適切に実施されるために、検査施設が満たさなければならない施設基準を提案する。

2. スクリーニング検査機能

検査施設は、現行のスクリーニング検査を迅速かつ正確に実施するとともに、確認検査および二次検査を実施して偽陽性率をできるだけ低くしなければならない。また、精密検査および患者の予後管理に必要な特殊検査にも対応できることが望ましい。

<解 説>

- i) 全てのスクリーニング検査（フェニルケトン尿症、メープルシロップ尿症、ホモシスチン尿症、ガラクトース血症、先天性甲状腺機能低下症、先天性副腎過形成症の6疾患）を同一検査施設で毎日実施できることが望ましい。
- ii) フェニルケトン尿症、メープルシロップ尿症、ホモシスチン尿症の検査では、ガスリー法、酵素法、HPLC法、タンデムマス法のいずれかでアミノ酸の測定ができる。なお、一次検査がガスリー法または酵素の場合、二次検査としてHPLC法によるアミノ酸の定量ができることが望ましい。
- iii) ガラクトース血症の検査では、一次検査としてペイゲンファージ法または酵素法でガラクトースの定量ができる。二次検査としてガラクトース-1-リン酸ウリジルトランスフェラーゼ活性およびウリジン2リン酸ガラクトース-4-エピメラーゼ活性の定性または定量検査ができることが望ましい。
- iv) 先天性甲状腺機能低下症の検査では、免疫学的測定法による甲状腺刺激ホルモン（TSH）の定量ができる。
- v) 先天性副腎過形成症の検査では、免疫学的測定法による17 α -ヒドロキシprogesterone（17-OHP）の定量ができる。二次検査として17-OHPの有機溶媒抽出法による免疫学的測定法による定量、またはHPLC-タンデム質量分析計による関連ステロイドの定量検査ができる。
- vi) コンサルタント医師および主治医の要請により、精密検査および治療管理のための濾紙血液検体によるアミノ酸、ガラクトース、TSH、17-OHPの定量検査およびガラクトース代謝関連酵素活性の定性または定量検査ができる。

3. 精度保証体制

検査前、検査時、検査後における精度保証体制が確立されていて、内部監査システムと組織内の責任体制が明確化されている。

<解説>

- i) 検査前の精度保証としては、採血医療機関における採血時期、採血手技、採血量、採血用濾紙・採血後の濾紙血液の管理、検体の迅速な送付、周産期のヨード含有消毒剤による先天性甲状腺機能低下症の不要な偽陽性者増加対策、出生体重2,000g未満の児の2回目採血の確保等について適切に助言できる。
- ii) 検査時の精度管理としては、適切な検体受付、検体前処理、使用機器の保守管理、使用する試薬の品質管理、日本マス・スクリーニング学会が推奨する内部精度管理等が実施可能で、外部精度管理に参加して定期的に自施設の正確度の評価を受けることができる。
- iii) 検査後の精度管理としては、適切な検査成績報告、要再採血・精密検査対象者の適切な管理、要精密検査対象者または患者の短期・長期フォローアップ情報を把握できる。
- iv) スクリーニング検査で得られた個人情報および検査済み濾紙血液検体を実施要綱等の規定に基づいて適切な管理ができる。

4. 施設規模と要件

検査施設は、都道府県・政令指定都市（以下、都道府県等という）ごとに1施設が設置されるのが原則であるが、年間出生数が3万人に達しない都道府県等では近隣の適切な検査施設に委託することが想定されることから、検査施設は年間3万検体以上を受託できる能力を有していることが望ましい。外部に委託する場合においても、検査施設は都道府県等の自治体ごとにスクリーニング結果とフォローアップ情報を把握しなければならない。

<解説>

- i) 現行の6疾患のスクリーニングでは、検査数が少ないと患者を発見する機会が乏しく検査精度の低下を招く恐れがある。経済的にも年間検査数が3万検体以下の場合、コスト増を招き、費用対効果が低下する。
- ii) 検査施設は、新生児マス・スクリーニングに関する知識と技術を有する検査技術者を配置し、適切な設備を有していることが必要である。

5. 検査技術者、事務職員

- (1) スクリーニング検査従事者数は、1検査施設（年間検査数3万検体）当たり検査技術者2名以上、受付・検査成績発行などの事務職員1名がそれぞれ専任として確保されている。
- (2) 検査技術者は、日本マス・スクリーニング学会認定技術者制度で認定された者がいることが望ましい。
- (3) 検査技術者は、スクリーニング検査に従事する前に新生児マス・スクリーニングに関する教育訓練を受け、従事後も少なくとも1年に1回以上専門研修の受講や関連学会への出席などにより、最新の知識の習得と技術の向上を図ることが必要である。

6. コンサルタント医師の委嘱

検査施設は、都道府県等の新生児マス・スクリーニング担当部署と連携し、先天性代謝異常疾患および小児内分泌疾患の専門医（日本先天性代謝異常学会員または日本小児内分泌学会員でありかつ日本マス・スクリーニング学会員である者）をコンサルタント医師として委嘱し、スクリーニン

グ検査に関する指導を受ける体制を整備しておかなければならない。

<解説>

- i) 検査施設は、コンサルタント医師から定期的に通常検査の指導を受けることによりスクリーニング検査の精度を確保する。
- ii) 検査施設は、コンサルタント医師から必要に応じて検査結果の判定に適切な助言と指導を受けられるようにする。また、地域のコンサルタント医師でも判断が難しい場合、コンサルタント医師とともに全国ネットワークと連携して対象疾患に精通した専門医による助言指導をいつでも受けられるようにする。
- iii) 検査施設は、精密検査が必要となった場合、それぞれの疾患毎に対応可能な精密検査機関への迅速な連絡が可能な体制を整備する。

7. 地域連絡協議会

検査施設は、スクリーニング実施主体の自治体が設置・運営する、採血医療機関（医師会産婦人科医会および小児科医会等）、検査機関（検査施設）、精密検査・治療機関（大学病院等専門医療機関）および自治体行政機関（保護者への広報・教育および事後措置等を行う自治体の母子保健担当部局、保健所、保健センター等）の代表者で組織される新生児マス・スクリーニング連絡協議会（仮称）に積極的に参加して地域の新生児マス・スクリーニング体制の維持とその向上に貢献する。

<解説>

- i) 新生児マス・スクリーニングを有効に行うためには、検査ばかりでなく、社会啓発、適切な濾紙血液検体の採取、検査結果を正確に報告する体制、必要に応じて再採血や精密検査等の対応を迅速に実施できる体制が不可欠であり、関係機関が定期的に問題点を検討することにより継続的に水準を維持、改善していくことが求められる。
- ii) 短期・長期のフォローアップによるスクリーニング陽性者の診断・治療状況、予後調査、および見逃し例の調査を確実に実施するためには、関係機関・関係者で構成する連絡協議会での検討が必須である。

8. 検査施設長、部門長、行政担当者

検査施設長、部門長、行政担当者は、日本マス・スクリーニング学会の会員であることが望ましい。

<解説>

検査施設は、マス・スクリーニング関連機関の中で、マス・スクリーニング関する多くの情報を把握できる立場にある。従って、検査施設では自施設での検査実施状況ばかりでなく採血医療機関の採血実施状況、および精密検査医療機関の精査・診断・治療状況に関するデータの収集と解析業務も担当すべきである。加えて、マス・スクリーニングに関する新しい情報、技術向上、および地域連絡協議会での協議に基づくシステムの改善等に中心的な役割を果たすことが望まれる。このような業務の遂行には、検査施設長、部門長、行政担当者の理解と支援が必須であり、日本マス・スクリーニング学会の会員として必要な情報の収集に努める必要がある。

制定日：平成22年3月

（この施設基準は、日本マス・スクリーニング学会誌19(3): 266-268に案を投稿し、パブリックコメントを求めたものである。）

